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Abstract
Background: The 5-year survival of patients with resected pancreatic adenocarcinoma is still
unsatisfying. The ESPAC-1 and the CONKO 001 trial proofed that adjuvant chemotherapy
improves 5-year survival significantly from approximately 14% to 21%. In parallel, investigators from
the Virginia Mason Clinic reported a 5-year survival rate of 55% in a phase II trial evaluating a
combination of adjuvant chemotherapy, immunotherapy and external beam radiation (CapRI-
scheme). Two other groups confirmed in phase II trials these results to a certain extent. However,
these groups reported severe gastrointestinal toxicity (up to 93% grade 3 or 4 toxicity). In a
randomized controlled phase III trial, called CapRI, 110 patients were enrolled from 2004 to 2007
in Germany and Italy to check for reproducibility. Interestingly, much less gastrointestinal toxicity
was observed. However, dose-reduction due to haematological side effects had to be performed
in nearly all patients. First clinical results are expected for the end of 2009.
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Methods/Design: CapRI-2 is an open, controlled, prospective, randomized, multicentre phase II
trial with three parallel arms. A de-escalation of the CapRI-scheme will be tested in two different
modifications. Patients in study arm A will be treated as outpatients with the complete CapRI-
scheme consisting of cisplatin, Interferon alpha-2b and external beam radiation and three cycles of
5-fluorouracil continuous infusion. In study arm B the first de-escalation will be realised by omitting
cisplatin. Next, patients in study arm C will additionally not receive external beam radiation. A total
of 135 patients with pathologically confirmed R0 or R1 resected pancreatic adenocarcinoma are
planned to be enrolled. Primary endpoint is the comparison of the treatment groups with respect
to six-month event-free-survival. An event is defined as grade 3 or grade 4 toxicity, objective
tumour recurrence, or death.
Discussion: The aim of this clinical trial is to evaluate de-escalation of the CapRI-scheme. It is
hypothesised that removal of cisplatin and radiotherapy will have no significant effect or only a
minor impact on the clinical response but result in substantially lower toxicity.
Trial Registration: Current Controlled Trials ISRCTN79802092
Background
Only 10–20% of patients with pancreatic cancer can be
resected with curative intention at the time of diagnosis.
Unfortunately, loco-regional recurrence and/or metastatic
disease develop in the majority of patients who undergo
pancreatic resection. Most patients typically relapse
within 9–15 months form initial presentation and have
median life expectancies of only 12–15 months without
adjuvant therapy. The 5-year survival of patients with
resected pancreatic adenocarcinoma is approximately
14% for patients without adjuvant therapy [1]. Data from
two randomized clinical phase III trials showed that adju-
vant chemotherapy results in significant increase of over-
all survival (OS) and disease-free survival (DFS) [2,3].
Therefore, adjuvant therapy with either 5-FU or gemcitab-
ine is recommended according to the German S3 guide-
lines for exocrine pancreas carcinoma [4].
Investigators form the Virginia Mason Clinic reported data
from a phase II trial where in an adjuvant setting cisplatin,
5-FU, interferon-α2b (INF-α2b) and external beam radia-
tion were administered. They reported from 43 patients
overall 5-year survival data of 55% [5]. The randomized,
open, controlled, prospective, multi-centre phase III CapRI-
trial was initiated in August 2004 to confirm the excellent
results of the CapRI-regimen [6]. The last patient was
enrolled end of 2007. First clinical results are expected for
2009. ACOSOG and the group of Linehan et al. confirmed
in phase II trials the results from the Virginia Mason Clinic
to a certain extent [7,8]. These excellent results could be
ascribed to the several synergistic effects between the com-
bined substances. Radio-sensitising properties of 5-FU and
cisplatin are well known. The incorporation of INF-α2b
into a combined modality treatment program seems to
offer a number of theoretical advantages. These include: 1)
the radio-sensitization effects of INF-α2b and 5-FU [9,10];
2) enhanced 5-FU based bio-availability; 3) a synergistic
inhibition of pyrimidine metabolism with 5-FU and 4) an
independent immunomodulatory effect of INF-α2b [11].
Furthermore, our own data derived from the translational
program accompanying the CapRI trial showed especially
immunomodulatory and anti-angiogeneic effects of INF-
α2b [12-17].
However, especially the ACOSOG group reported severe
gastrointestinal toxicities (93%) which led to enrolment
stop. Virginia Mason Clinic reported 70% grade 3 or 4 tox-
icity and the group from the Washington-University
stated 36% gastrointestinal toxicity. Although the final
safety analysis is not yet performed we could give account
on less GI-toxicity in the CapRI-trial. Nevertheless, the
regimen is challenging and reduction of side effects is a
useful goal.
Methods/Design
Trial organisation and coordination
CapRI-2 is designed and coordinated by the Department
of Surgery, University of Heidelberg and the National
Center for Tumor Diseases, Heidelberg (NCT). Heidelberg
is responsible for overall trial management, regulatory
affairs, statistical planning and analysis, trial registration
and reporting as well as quality assurance. The responsi-
bility for external monitoring and pharmacovigilance is
carried forward to independent Contract Research Organ-
isations (CRO). The trial will be conducted by a German
network for pancreatic carcinoma (PC-Net) including the
University hospitals of Munich (Technische Universität),
Marburg, Ulm, Greifswald, Halle and Heidelberg. Further
study centres will be recruited. The trial is sponsored by a
private person, Dr. Wild from Germany. The financial
sponsor is not involved in the database management and
has no access to the randomisation code.BMC Cancer 2009, 9:160 http://www.biomedcentral.com/1471-2407/9/160
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Investigators
Patients will be recruited by the centres who will commit
their participation. Due to the multimodal nature of the
trial, all investigators will either be experienced oncolo-
gists, gastroenterologists, radio-oncologists or surgeons.
Data Safety and Monitoring Board
An independent Data Safety and Monitoring Board
(DSMB) consisting of three experts (one expert in oncol-
ogy, one in pancreatic carcinoma and one in biometry/
biostatistics) will evaluate the clinical research data on an
ongoing basis to assure patient safety and study integrity
for the study. The board will monitor the trial data, in par-
ticular the safety data, and makes recommendations
based on the periodically reviewed data. Responsibilities
are laid down in a DSMB Charta.
Medication supply
All chemotherapeutic and immunotherapeutic agents will
be prepared and provided by the corresponding phar-
macy. Medication will be prepared for each patient specif-
ically and delivered just prior to administration to the
outpatient's department.
On-site Monitoring
Monitoring on site will be performed according to good
clinical practice (GCP) guidelines. Monitoring will be done
by personal visits from clinical monitors according to the
SOPs of the independent, external CRO. Monitors will
review the entries into CRFs on the basis of source docu-
ments (30% source data verification). Data management
will be performed by the same CRO. Pharmacovigilance is
outsourced to a further CRO specialized on safety issues.
Both data bases will be aligned at the end of the trial.
Ethics approval and informed consent
The final protocol was approved by the ethics committee
of the University of Heidelberg; Medical School (AFmu-
071/2008) at May 16th 2008. This clinical trial complies
with the Helsinki Declaration from 2004, the Medical
Association's professional code of conduct, the principles
of GCP guidelines and the Federal Data Protection Act.
The trial will also be performed in keeping with local legal
and regulatory requirements. The medical secrecy and the
Federal Data Protection Art will be followed.
Written informed consent will be obtained from each patient
in oral and written form before inclusion in the trial and the
nature, scope and possible consequences of the trial have
been explained by a physician in detail. The investigator will
not undertake any measures specifically required only for the
clinical trial until valid consent has been obtained.
Patient selection
CapRI-2 focuses on hospitalised patients over 18 years of
age with resected pancreatic adenocarcinoma during a 24
months period and started in October 2008. Men and
women over 18 years of age with histological proven R0
or R1 resected [18] pancreatic adenocarcinoma will be
screened for participation in the clinical trial. Patients will
be contacted first-time by the (sub-) investigators either
during their postoperative hospital stay or after discharge
at the outpatient's department. A detailed overview of
recruitment criteria for inclusion and exclusion is given in
table 1.
Study design
CapRI-2 is an open, controlled, prospective, randomized,
multicentre phase II trial with three parallel study arms.
Patients in study arm A receive a combination of 5-FU, cis-
platin and external beam radiation including INF-α2b
administration (CapRI). The first de-escalation step is in
study arm B where cisplatin is omitted (CapRI-light). The
second de-escalation will be tested in study arm C where
beside cisplatin also radiotherapy is cancelled (CapRI-
ultra-light). These treatments are offered to a heterogene-
ous group of people under clinical circumstances, cover-
ing a wide range, for both sexes and with heterogeneous
characteristics/co-morbidities. No interim analysis is
planed for this trial.
Study objectives
Primary objective is the comparison of the treatment
groups with respect to six-month event-free survival. An
event is defined as tumour recurrence, grade 3 or grade 4
toxicity (according to CTCAE Version 3.0), or death
(whichever occurs first). Secondary objectives are compar-
ison of the treatment groups with respect to safety, OS,
Recurrence-Free Survival (RFS), Quality of Life (QoL),
screening for predictive markers, and accompanying
translational research focussing mainly on immunologi-
cal parameters.
Randomisation
All patients enrolled will be identifiable throughout the
study. The investigator will maintain a personal list of
patient numbers and patient names to enable records to
be found at a later date. Upon inclusion each patient
receives a unique identification number. After the
patient's eligibility for randomisation has been assessed
he/she will be randomly assigned to one of the three treat-
ment arms (1:1:1 randomization) and receive a unique
randomisation number. By the randomisation number, it
is possible to identify the order in which the patients
entered the randomized study period at the centre in
question. Randomisation will be stratified by centre; it
will be done and documented centrally and send by fax.
The randomisation list will be kept in safe and confiden-
tial custody at the involved CRO. The method of randomi-
sation (whether fixed block size or randomly determined
block size) and the block sizes themselves will not be dis-
closed to the study centres, the monitors or any other per-BMC Cancer 2009, 9:160 http://www.biomedcentral.com/1471-2407/9/160
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son involved in the study conduct. This information will
be kept with the randomisation list.
Treatment scheme
After implantation of a Port-A-Cath catheter patients will
be treated as follows (see figure 1): All arms: 200 mg/m2/
day 5-FU by continuous intravenous infusion on days 1–
38; 64–101, and 120–161; three million units IFN-α2b
subcutaneous three times weekly days 1–38 plus one injec-
tion prior to treatment start given during week -1 (approx.
day -6). Non-steroidal anti-inflammatory drugs and ster-
oids should be avoided if possible during IFN-α2b treat-
ment. Only arm A and B: Beside 5–FU and IFN-α2b
patients will be treated with external beam radiation: The
pancreatic bed will be covered with a minimum margin of
2 cm. The porta hepatis, origins of the celiac axis and supe-
rior mesenteric artery will be included. The fields must
include the entire duodenal C-loop as seen on pre-opera-
tive CT scan. Total dose will be 50.4 Gy in 28 fractions over
5.5 weeks (1.8 Gy/day). Simulation should be done with
the patient in the supine position with "arms up" position.
A treatment planning CT is required to allow 3-D confor-
mal treatment planning. Conventional 3-D treatment tech-
niques as well as intensity modulated radiotherapy (IMRT)
could be used for radiotherapy. At least a four field tech-
nique for 3-D planning or a multi-field technique for IMRT
is necessary. Furthermore a multi-leaf collimator is required
to allow customized blocking and IMRT. Equipment:
greater than or equal to 6 MeV photons should be used.
Only study arm A): Cisplatin 30 mg/m2 IV over 60 minutes
on days 1, 8, 15, 22, 29, 36 (6 doses). Two to three hours
before and after Cisplatin dose the patients will receive
hydration of at least 2 litres. Patients will be taught to drink
at least 1 litre during the day.
Evaluations, Toxicity-Based Dose Adjustment and follow-
up
Pre-treatment evaluation for patients who are enrolled
includes a single low dose (3 Mio U) injection of INF-α2b
prior to therapy. Blood will be drawn for intensive immu-
nological studies. All patients must have appropriate lab
and radiographic studies conducted prior to study enrol-
ment to meet eligibility criteria. Lab parameters will be
obtained at least weekly and imaging will be performed
every three months. The patients will be asked at each visit
for any adverse event (AE) and concomitant medication.
Quality of life (QoL) questionnaires (QLQ-C30 and the
pancreas-specific Pan 26 questionnaire) will be handed
out to the patients prior to therapy and after each cycle of
chemotherapy. Samples for translational research (blood,
plasma and urine) will be collected at the indicated time
points (prior and 24 hours after first IFN-α2b administra-
tion, immediately prior to therapy start, first day of week
3 and at staging visits) and either analyzed immediately or
kept frozen at -80°C until further analysis. Samples will
be collected at each site and shipped on dry ice twice a
year to Heidelberg.
Decisions regarding weekly chemoradiation treatment
and chemotherapy dose-adjustment will be made using
Table 1: Eligibility Criteria
Inclusion criteria Exclusion criteria
￿ R0/R1 resected pancreatic ductal adenocarcinoma ￿ Metastatic disease
￿ Adequate lab parameters (bone marrow-, liver and kidney function; Hb 
>8.0 g/dl, WBC >3,000 cells/mm3, platelets >75,000 cells/mm3; ALT/AST 
≤ 2 ULN; Creatinine ≤1.5 mg/dL and calculated or measured creatinine 
clearance (CrCl) of ≥ 60 ml/min).
￿ Previous chemo- or radiotherapy for pancreatic carcinoma
￿ Therapy starts within eight weeks after surgery ￿ Previous radiotherapy in the corresponding region
￿ Ability of patient to understand character and individual consequences 
of clinical trial
￿ Patients with known severe depression
￿ Written informed consent must be available before enrolment in the 
trial
￿ Patients with severe heart diseases (NYHA stadium three and four) or 
severe lung disease (COPD Grade III, Asthma bronchiale Grade IV)
￿ For women with childbearing potential, adequate contraception. ￿ General condition worse than ECOG 2
￿ Age ≥ 18 years ￿ Pregnancy and lactation
￿ History of hypersensitivity to the investigational product or to any 
drug with similar chemical structure or to any excipient present in the 
pharmaceutical form of the investigational product
￿ Any contraindication met for any investigational product
￿ Patients with mental diseases ICD-10-code F30, F31, F32.2 ff. or F33.2 
ff.
￿ Participation in other clinical trials and observation period of 
competing trials, respectively.
￿ Serious uncontrolled acute infections at the time of therapy initiation 
or patients with known HIV infection, other immunodeficiencies or 
autoimmune diseasesBMC Cancer 2009, 9:160 http://www.biomedcentral.com/1471-2407/9/160
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Treatment scheme Figure 1
Treatment scheme.BMC Cancer 2009, 9:160 http://www.biomedcentral.com/1471-2407/9/160
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the guidelines below and based on haematological
parameters monitored twice weekly during chemo-
(radio)therapy. In case of grade 3/4 haematological toxic-
ities chemotherapy should be held until resolution or
until toxicity has resolved or dropped to a Grade 2 level.
Radiation will be continued. IFN-α2b will be stopped in
case of grade 4 haematological toxicities. The procedure
for patients with leukocytes between 1.0 and 1.5/nl will
be discussed individually in the study group. In case of
grade 3/4 GI toxicities (including anorexia, dehydration,
nausea/vomiting, diarrhoea, mucositis and bleeding)
patients will be considered for periodic outpatient intrave-
nous rehydration with anti-emetics according to conven-
tional practice guidelines. Corticosteroids should be
avoided. Any grade > 2 oto-, neuro-, or nephrotoxicity
should lead to discontinuation of cisplatin until recovery
to at least grade 1. All uncertain cases of toxicities will be
discussed by the study group and a decision will be made
according to the study group discretion. Patients will be
investigated weekly for mental state. In case of psycholog-
ical features, a psychiatrist will be consulted. Patients with
mental diseases will be excluded.
Patients can withdraw from study participation at any
time. Patients are taken off the study if unacceptable tox-
icity appears. Unacceptable toxicity is defined as serious
side effects or irreversible Grade 4 toxicity independent
whether they are expected or unexpected. Patients with
mental diseases will be excluded as mentioned in exclu-
sion criteria. Patients who withdraw from the study may
be treated with 5-FU and folinic acid or with gemcitabine.
The decision will be based on the individual reason of
study withdrawal. Treatment with gemcitabine is recom-
mended to patients with recurrence of disease. At the
moment, no further therapy is recommended after com-
pletion of adjuvant therapy. Patients will undergo imag-
ing and lab analysis (including tumor marker) quarterly
and will be tracked by quarterly phone follow-up until
death.
Statistical considerations and sample size estimation
The primary endpoint in this clinical trial is the event-free
survival. An event is defined as time from resection to
objective tumour recurrence, grade 3 or grade 4 toxicity
(according to CTCAE Version 3.0), or death (whichever
occurs first). Secondary endpoints are as follows: a) OS,
defined both as time from randomization and resection to
death; b) RFS, defined as either time from randomization
or as time from resection to relapse of death from any
cause (whichever occurs first); c) QoL; d) Translational
research focussing on immunological and angiogenic
parameters, and e) safety issues.
For each parameter, several (longitudinal) measurements
will be available. Apart from the parameter values them-
selves, further parameters will be generated, such as differ-
ences, or relative differences, of values after vs. before
administration of INF-α2b or binary variables obtained
by applying threshold values. Sample size calculations
were based on the three-group comparison (differences in
the three 6-month event-free rates r1, r2, r3 corresponding
to CapRI (Arm A), CapRI light (Arm B), and CapRI ultra
light (Arm C), respectively and carried out by means of
computer simulations using the following main assump-
tions: equal group sizes, failure times arising from an
exponential distribution, individual follow-up duration
of ≥ 6 months, duration of patient enrolment 6, 12, or 18
months, For r1 = 2%, r2 = 10%, r3 = 15% the minimal
sample size leading to an estimated power of ≥ 80% was
37 per group. Similarly, for r1 = 2%, r2 = 5%, r3 = 15% the
necessary sample size estimated by the simulations was 38
per group. From the experience gained during the CapRI
trial it can be expected that about 15% of the patients
refuse further participation in the trial (including further
follow-up examinations) once the result of the randomi-
zation has been disclosed to them. These patients do not
contribute any information to the endpoints of this trial.
In order to accommodate for a maximum drop-out rate of
15% the total sample size is therefore increased to 135.
The main evaluation will be performed two years after the
last patient's enrolment.
The assessment of safety will be based mainly on the fre-
quency of AEs and on the number of laboratory values
that fall outside of pre-determined ranges and/or show
prominent worsening from baseline. AEs will be summa-
rized by presenting the number and percentage of patients
having any AEs or serious adverse events (SAE) and having
each individual AE, and by determining and summarizing
the maximum individual toxicity grade (over all forms of
toxicity) for each treatment cycle. Furthermore, the most
common AEs (those occurring in at least 10% of the treat-
ment group) will be determined. Any other information
collected (e.g. severity or relatedness to study drug) will be
listed as appropriate. Laboratory data will be summarized
by presenting shift tables using normal ranges (baseline to
most extreme post-baseline value) and by presenting sum-
mary statistics of raw data and change from baseline val-
ues (means, medians, standard deviations, ranges). The
analysis of safety and tolerability will be based on all
patients entered into treatment who received at least two
cycles of the systemic study therapy (= per protocol popu-
lation of this study). All proportions will be given along
with exact Pearson-Clopper 95% confidence bounds.
Discussion
Only 10–20% of patients with pancreatic cancer can be
resected with curative intention at the time of diagnosis
[19]. The 5-year survival of patients with resected pancre-
atic adenocarcinoma is approximately 14% for patientsBMC Cancer 2009, 9:160 http://www.biomedcentral.com/1471-2407/9/160
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without adjuvant therapy [1]. Data from two randomized
clinical phase III trials showed that adjuvant chemother-
apy results in significant increase of overall survival and
disease-free survival [2,3]. The Virginia Mason study
group in Seattle, USA, published very promising data in a
phase II trial involving immunotherapy and chemo-radi-
ation in the adjuvant setting [5]. The reliability of the data
has been intensively discussed and therefore a source-
data-verification was performed by the National Cancer
Institute (NCI). Finally, the reference adjuvant treatment
regimen from a RCT [2] and the very promising data from
a phase-II trial [5] were the basis for the randomized, con-
trolled multicentre CapRI-trial [6]. First clinical results are
expected for 2009.
So far, the observed toxicity in the CapRI trial is less than
reported from the Virginia Mason Clinic and other groups
in USA. This might be due to differences in radiation treat-
ment and supportive care during chemotherapy. How-
ever, the CapRI-scheme is nonetheless a quite toxic
regimen. In our experience haematological side effects
dominate, followed by gastrointestinal toxicity. Most of
the toxicities are thought to be related to cisplatin. Fur-
thermore, in vivo data indicate that the combination of 5-
FU and INF-α2b is responsible for the anti-tumour effect
[12,13,16,17]. Moreover, there are data supporting the
idea that radiotherapy is of low effectiveness [2,20,21].
Therefore, it is hypothesized that removal of cisplatin and
radiotherapy will have no significant effect or only a
minor impact on the clinical response but result in lower
toxicity. The current clinical trial, CapRI-2, will investigate
this hypothesis on the basis of a de-escalation of the
CapRI-regimen. CapRI-2 is a phase II trial focussing on
event-free survival. Obviously, it has to be expected that
toxicity decreases when less chemotherapy is adminis-
tered. However, as recurrence and death are defined as
events too, some insights into clinical relevance of the de-
escalating schemes could be made. As a phase II trial the
comparison of OS can not be the primary objective of this
trial and moreover, a trial design showing equality or non-
inferiority regarding survival and superiority regarding
toxicity would need thousands of patients. The results of
CapRI-2 will bring hints whether and which de-escalation
might be worth to be investigated in further trials. The
results of the CapRI-2-trial will advance clinical and scien-
tific knowledge on the adjuvant treatment of pancreatic
adenocarcinoma as it may help to improve clinical results
on the one hand and reduce therapeutic-related toxicities
on the other.
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